Cargando…
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480221/ https://www.ncbi.nlm.nih.gov/pubmed/37669923 http://dx.doi.org/10.1038/s41392-023-01589-z |
_version_ | 1785101745696800768 |
---|---|
author | Xie, Xin Yu, Tingting Li, Xiang Zhang, Nan Foster, Leonard J. Peng, Cheng Huang, Wei He, Gu |
author_facet | Xie, Xin Yu, Tingting Li, Xiang Zhang, Nan Foster, Leonard J. Peng, Cheng Huang, Wei He, Gu |
author_sort | Xie, Xin |
collection | PubMed |
description | Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human diseases and has attracted substantial efforts in the field of medicine. Therefore, in this review, we focus on the recent development of drug discovery targeting “undruggable” proteins and their application in clinic. To make this review well organized, we discuss the design strategies targeting the undruggable proteins, including covalent regulation, allosteric inhibition, protein–protein/DNA interaction inhibition, targeted proteins regulation, nucleic acid-based approach, immunotherapy and others. |
format | Online Article Text |
id | pubmed-10480221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104802212023-09-07 Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials Xie, Xin Yu, Tingting Li, Xiang Zhang, Nan Foster, Leonard J. Peng, Cheng Huang, Wei He, Gu Signal Transduct Target Ther Review Article Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human diseases and has attracted substantial efforts in the field of medicine. Therefore, in this review, we focus on the recent development of drug discovery targeting “undruggable” proteins and their application in clinic. To make this review well organized, we discuss the design strategies targeting the undruggable proteins, including covalent regulation, allosteric inhibition, protein–protein/DNA interaction inhibition, targeted proteins regulation, nucleic acid-based approach, immunotherapy and others. Nature Publishing Group UK 2023-09-06 /pmc/articles/PMC10480221/ /pubmed/37669923 http://dx.doi.org/10.1038/s41392-023-01589-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Xie, Xin Yu, Tingting Li, Xiang Zhang, Nan Foster, Leonard J. Peng, Cheng Huang, Wei He, Gu Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
title | Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
title_full | Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
title_fullStr | Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
title_full_unstemmed | Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
title_short | Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
title_sort | recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480221/ https://www.ncbi.nlm.nih.gov/pubmed/37669923 http://dx.doi.org/10.1038/s41392-023-01589-z |
work_keys_str_mv | AT xiexin recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT yutingting recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT lixiang recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT zhangnan recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT fosterleonardj recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT pengcheng recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT huangwei recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials AT hegu recentadvancesintargetingtheundruggableproteinsfromdrugdiscoverytoclinicaltrials |